MedPath

Transfusion Requirements After Orthotopic Liver Transplantation

Not Applicable
Withdrawn
Conditions
Anemia
Registration Number
NCT01435746
Lead Sponsor
University Medical Center Goettingen
Brief Summary

The objective of this trial is to evaluate different transfusion strategies in patients after liver transplantation. Patients in the experimental arm will be given red blood cell (RBC) transfusion according to a liberal strategy, i. e., transfusions should be given, when hemoglobin concentration falls below 10 g/dl, and hemoglobin concentration should be maintained between 10 and 12 g/dl. Patients in the control arm will be given red blood cell (RBC) transfusion according to a restrictive strategy, i. e., transfusions should be given, when hemoglobin concentration falls below 8 g/dl, and hemoglobin concentration should be maintained between 8 and 10 g/dl.

Detailed Description

Not available

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Patients undergoing liver transplantation
  • Patients considered to have euvolemia after initial treatment by attending physicians
Exclusion Criteria
  • Patients age 18 or less
  • Patients undergoing combined liver-kidney transplantation
  • Patients requiring renal replacement therapy before liver transplantation for longer than two weeks
  • Inability to receive blood products
  • Patient with active blood loss at the time of enrollment
  • Pregnancy
  • Imminent death

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Composite of death, graft loss and renal failure30 days after randomization
Secondary Outcome Measures
NameTimeMethod
Renal function30 days after randomization

Renal function will be assessed by estimated glomerular filtration rate

Trial Locations

Locations (1)

University Medical Center Göttingen

🇩🇪

Göttingen, Niedersachsen, Germany

University Medical Center Göttingen
🇩🇪Göttingen, Niedersachsen, Germany

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.